US biopharmaceutical company Pfizer Inc (NYSE:PFE) announced on Wednesday that it has entered into an exclusive licensing agreement with biotechnology company Starna Therapeutics to develop and commercialise three preclinical in vivo chimeric antigen receptor T-cell (CAR-T) programmes targeting autoimmune diseases outside Greater China.
The agreement also grants Pfizer rights to use Starna's proprietary in vivo CAR-T technology in inflammation and immunology, as well as oncology.
Starna will receive an upfront payment of USD330m and is eligible for up to USD2.3bn in development and commercial milestone payments, in addition to royalties on net sales of approved products. Pfizer will lead clinical development outside Greater China and manufacture finished drug products for initial clinical trials at its US facilities.
Pfizer will retain exclusive commercialisation rights outside Greater China and hold options to expand its licensing territory to include the region. The agreement also provides options to exclusively license compounds developed under a separate research collaboration.
The deal expands Pfizer's Inflammation and Immunology pipeline, leveraging its expertise in RNA delivery, immunology research, clinical development and commercialisation to advance next-generation cell therapies for autoimmune diseases and cancer.
Rakuten Medical launches Phase 1 first-in-human trial of PD-L1-targeted RM-0256 photoimmunotherapy
BioArctic and Eisai report positive five-year data for Leqembi in early Alzheimer's disease
Akeso submits sNDA for ivonescimab chemotherapy combination in first-line biliary tract cancer
AstraZeneca rare disease unit secures US and EU approvals for Klygefa in myasthenia gravis
Genentech secures first FDA approval for primary membranous nephropathy treatment
Aelis Farma announces receipt of second positive safety recommendation for Down syndrome trial
Specialised Therapeutics' YONDELIS sarcoma therapy approved in Thailand
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism
Eisai launches subcutaneous Leqembi Pen in Japan for early Alzheimer's disease
Breakthrough T1D and Walgreens Foundation join forces to support the type 1 diabetes community
Innovent Biologics presents preclinical data for IL-6/TL1A bispecific antibody IAR177
Traws Pharma reports final Phase 2a COVID-19 data and advances influenza programme